Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | TYMP | P19971 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138243 | 0.80 | NR3C1 (0.77) | NR3C1MEN1TSHRMAPK1KMT2A | |
| SCHEMBL4138308 | 0.80 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL2672885 | 0.80 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL4142934 | 0.77 | NR3C1 (1.00) | NR3C1NR3C2PGRTYMP | |
| SCHEMBL4151405 | 0.75 | NR3C1 (1.00) | NR3C1NR3C2PGRTYMP | |
| SCHEMBL4135206 | 0.75 | NR3C1 (1.00) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL4404706 | 0.75 | NR3C1 (0.85) | NR3C1NR3C2PGR | |
| SCHEMBL4138431 | 0.75 | NR3C1 (1.00) | NR3C1NR3C2PGRTYMP | |
| SCHEMBL11000972 | 0.75 | DRD4 (0.53) | DRD2DRD4DRD3SLC6A5MEN1 | |
| SCHEMBL4135209 | 0.73 | NR3C1 (1.00) | NR3C1NR3C2PGRTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173664-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173664-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, TYMS | NR3C1 1/4885NR3C2 2/4885PGR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.